# Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD

> **NCT01393145** · PHASE3 · WITHDRAWN · sponsor: **Ache Laboratorios Farmaceuticos S.A.**

## Conditions studied

- Chronic Obstructive Pulmonary Disease
- COPD

## Interventions

- **DRUG:** Combination Fluticasone /Formoterol 12/250 μg
- **DRUG:** Seretide Diskus (salmeterol/fluticasone) 50/250 μg

## Key facts

- **NCT ID:** NCT01393145
- **Lead sponsor:** Ache Laboratorios Farmaceuticos S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-08
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01393145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01393145, "Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01393145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*